Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Imidazo[1,5-a]pyrido[3,2-e]pyrazine, 6,7-dimethyl-9-propyl- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

959705-78-3

Post Buying Request

959705-78-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

959705-78-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 959705-78-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,9,7,0 and 5 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 959705-78:
(8*9)+(7*5)+(6*9)+(5*7)+(4*0)+(3*5)+(2*7)+(1*8)=233
233 % 10 = 3
So 959705-78-3 is a valid CAS Registry Number.

959705-78-3Downstream Products

959705-78-3Relevant articles and documents

Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors

H?fgen, Norbert,Stange, Hans,Schindler, Rudolf,Lankau, Hans-Joachim,Grunwald, Christian,Langen, Barbara,Egerland, Ute,Tremmel, Peter,Pangalos, Menelas N.,Marquis, Karen L.,Hage, Thorsten,Harrison, Boyd L.,Malamas, Michael S.,Brandon, Nicholas J.,Kronbach, Thomas

supporting information; experimental part, p. 4399 - 4411 (2010/08/06)

Novel imidazo[1,5-a]pyrido[3,2-e]pyrazines have been synthesized and characterized as both potent and selective phosphodiesterase 10A (PDE10A) inhibitors. For in vitro characterization, inhibition of PDE10A mediated cAMP hydrolysis was used and a QSAR mod

PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM

-

Page/Page column 37, (2008/06/13)

The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 959705-78-3